An ASNC Information Statement: Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis
Resource Type
Information Statements, Practice Points
Year Published
2022
Related Resources
Cases
PET Case: Visual Perfusion vs Absolute Blood Flow: Differences in Imaging Agents
Case Summary This case illustrates how the differences in tracer extraction fraction…
ASNC Comments to CMS on 2027 HOPPS Proposed Rule
ASNC_Comments-on-2027-HOPPS-proposed-rule_08-31-2026
Cases
PET Case: The Mystery of Chest Pain with Patent Grafts
Case summary: This case illustrates the added value of myocardial blood flow…
